文献速递脊柱关节炎

C反应蛋白作为强直性脊柱炎治疗反应预测因素的作用

The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis.
PubMed 文献 · Semin Arthritis Rheum · 2018-11-02

该事后分析汇总了四项随机试验中接受依那西普治疗的867例强直性脊柱炎患者,评估基线CRP水平与第12周治疗反应的关系。结果显示,极高水平基线CRP(>3倍正常上限)是四项第12周结局的显著预测因素,而第2、4、8周CRP正常比CRP升高更能预测第12周反应。

要点

  • 极高水平基线CRP(>3倍正常上限)显著预测第12周ASAS20、ASAS50、ASDAS-CRP<1.3和ASDAS-CRP下降≥1.1。
  • 第2、4、8周CRP正常比CRP升高更能预测第12周治疗反应。
  • 患者报告结局作为反应预测因素的一致性不如CRP。

核心结论

  • 在强直性脊柱炎患者中,基线和基线后CRP水平均可预测第12周治疗反应,且一致性优于患者报告结局。

研究设计与样本

  • 事后分析,汇总四项随机试验中接受依那西普治疗的867例强直性脊柱炎患者数据。

主要发现

  • 867例患者中,基线CRP正常371例(43%),高水平299例(34%),极高水平197例(23%)。
  • 极高水平基线CRP与正常CRP相比,是全部四项第12周结局的显著预测因素。
  • 第2、4、8周CRP正常比CRP升高更能预测第12周反应。
  • 患者报告结局作为反应预测因素一致性较差。
  • 较高基线CRP与较低发病年龄(<40岁)显著相关,正常CRP与较低疾病负担显著相关。

关键数值与推荐

  • CRP正常定义为≤正常上限(≤ULN),升高定义为>ULN,高水平定义为>ULN且≤3倍ULN,极高水平定义为>3倍ULN。
  • 第12周反应评估指标包括ASAS20、ASAS50、ASDAS-CRP<1.3和ASDAS-CRP下降≥1.1。

临床怎么用

  • 临床可结合基线和治疗后早期(第2、4、8周)CRP水平预测强直性脊柱炎患者第12周对肿瘤坏死因子-α阻断剂的治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine whether C-reactive protein (CRP) level is predictive of response to tumor necrosis factor-α blocker treatment in patients with ankylosing spondylitis (AS) and whether there is an optimal CRP range for treatment initiation. METHODS: In this post hoc analysis, data on etanercept-treated patients with AS were pooled from four randomized trials. Week 12 responses (ASAS20, ASAS50, ASDAS-CRP < 1.3, and ASDAS-CRP ∆ ≤ 1.1) were evaluated in relationship to baseline CRP levels (normal, defined as ≤ upper limit of normal [≤ ULN]; elevated, > ULN; high, > ULN and ≤ 3xULN; and very high, > 3xULN), baseline levels of patient-reported outcomes (PROs), and CRP levels at weeks 2, 4, and 8, using univariate and stepwise predictor analyses. In addition, relationships between baseline CRP and other baseline predictors were analyzed using stepwise models of response. RESULTS: Among 867 patients, baseline CRP levels were normal in 371 (43%) patients, high in 299 (34%), and very high in 197 (23%). Very high baseline CRP was a significant predictor for all four week-12 outcomes, compared with normal CRP. Conversely, normal CRP at weeks 2, 4, and 8 was a stronger predictor of week 12 response than elevated CRP. PROs were less consistent predictors of response. In addition, there was a significant association between higher baseline CRP and lower age of disease onset (< 40 years) and between normal CRP and lower disease burden. CONCLUSIONS: In patients with AS, both baseline and post-baseline CRP levels can be predictive of response to treatment at week 12, more consistently than PROs. CLINICAL TRIALS: NCT00421915, NCT00247962, NCT00418548, NCT00356356.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Szumski A, Koenig AS, et al. The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. Semin Arthritis Rheum. 2018. PMID: 30473179. doi:10.1016/j.semarthrit.2018.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。